Pluvicto is NOT Superior to Orgovyx and Xtandi Combination—They Treat Different Disease States
Pluvicto (lutetium-177-PSMA-617) and the combination of Orgovyx (relugolix) plus Xtandi (enzalutamide) are not directly comparable because they are indicated for different stages of metastatic prostate cancer and serve distinct roles in the treatment algorithm.
Understanding the Treatment Landscape
Pluvicto's Specific Indication
Pluvicto is FDA-approved specifically for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) in patients who have ALREADY been treated with both an androgen receptor pathway inhibitor (like Xtandi) AND taxane-based chemotherapy 1. This is a late-stage, heavily pre-treated population.
The 2025 ASCO guidelines position Pluvicto as a treatment option after patients have progressed on ADT, ARPI (like Xtandi), and docetaxel—not as an alternative to these agents 2.
Orgovyx + Xtandi Combination's Role
The combination of Orgovyx (a GnRH antagonist providing androgen deprivation therapy) plus Xtandi (an ARPI) represents first-line or early-line therapy for metastatic castration-sensitive or castration-resistant prostate cancer, used BEFORE chemotherapy and BEFORE Pluvicto would even be considered.
The Sequential Treatment Algorithm
Based on current ASCO guidelines 2:
For treatment-naive metastatic prostate cancer:
- Start with ADT (like Orgovyx) + ARPI (like Xtandi) ± docetaxel
- This is the foundation of initial therapy
After progression on ADT + ARPI:
- Options include docetaxel chemotherapy, PARP inhibitors (if HRR mutations present), or alternative ARPIs
After progression on BOTH ARPI and docetaxel:
- NOW Pluvicto becomes an option (if PSMA-positive on imaging)
- Other options include cabazitaxel, radium-223 (bone-only disease), or olaparib (HRR mutations)
Emerging Evidence: Combination Strategies
The most relevant comparison involves combining Pluvicto with enzalutamide rather than choosing between them:
The ENZA-p trial 3, 4 demonstrated that adding Pluvicto to enzalutamide in first-line mCRPC (before docetaxel) significantly improved outcomes:
- PSA progression-free survival: 13.0 months vs 7.8 months (HR 0.43, p<0.0001)
- Overall survival: 34 months vs 26 months (HR 0.55, p=0.0053)
- Quality of life measures favored the combination
This represents a paradigm shift—using Pluvicto earlier in combination with ARPIs, not as a replacement.
Critical Caveats
PSMA Expression Required: Pluvicto requires PSMA-positive disease on PET imaging—not all patients qualify 1
Toxicity Profile: Pluvicto adds myelosuppression risk (anemia, thrombocytopenia), renal toxicity, and xerostomia that ARPIs alone don't cause 1
Access and Timing: Current FDA approval and guidelines still position Pluvicto post-ARPI/post-chemotherapy 2, though the ENZA-p data 4 may shift this in future guideline updates
Sequential vs Concurrent: The question of "superior to" implies replacement, but modern evidence suggests concurrent use may be optimal 3, 4
Bottom Line for Clinical Practice
Do not discontinue or avoid Orgovyx + Xtandi in favor of Pluvicto. These agents work at different disease stages. For newly diagnosed or early metastatic disease, start with ADT + ARPI combinations. Reserve Pluvicto for PSMA-positive disease after progression on ARPIs and chemotherapy per current FDA approval 1, or consider the combination approach if the patient meets ENZA-p trial criteria and you're practicing in a setting where this is feasible 3, 4.
The future likely involves integrating Pluvicto earlier with ARPIs based on ENZA-p data 4, but this represents addition, not substitution.